Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management

5Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

High-grade brain tumors are malignant tumors with poor survival and remain the most difficult tumors to treat. An important contributing factor to the development and progression of brain tumors is their ability to evade the immune system. Several immunotherapeutic strategies including vaccines and checkpoint inhibitors have been studied to improve the effectiveness of the immune system in destroying cancer cells. Recent studies have shown that kinase inhibitors, capable of inhibiting signal transduction cascades that affect cell proliferation, migration, and angiogenesis, have additional immunological effects. In this review, we explain the beneficial therapeutic effects of novel small-molecule kinase inhibitors and explore how, through different mechanisms, they increase the protective antitumor immune response in high-grade brain tumors.

Cite

CITATION STYLE

APA

Filippone, A., Mannino, D., Casili, G., Lanza, M., Paterniti, I., Cuzzocrea, S., … Esposito, E. (2022, December 1). Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms232415693

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free